Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2010 |
| End Date: | December 2010 |
This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3
doses of AGN-207281 based on an ongoing review of data during the study period compared with
timolol ophthalmic solution or placebo in patients with ocular hypertension or primary
open-angle glaucoma.
doses of AGN-207281 based on an ongoing review of data during the study period compared with
timolol ophthalmic solution or placebo in patients with ocular hypertension or primary
open-angle glaucoma.
Inclusion Criteria:
- Ocular hypertension or primary open-angle glaucoma in each eye
- Requires IOP-lowering therapy in both eyes
- Visual acuity score of 20/100 or better in each eye
Exclusion Criteria:
- Experienced significant weight change (over 10 pounds) within 60 days
- History of alcohol or drug addiction
- History of migraines or frequent headaches
- Anticipated wearing of contact lenses during the study
- Required chronic use of ocular medications during study
- Eye surgery within 6 months
- Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months
- Use of oral, intramuscular, intravenous corticosteroids within 21 days
- Use of ophthalmic corticosteroids within 2 months
We found this trial at
1
site
Click here to add this to my saved trials
